Tandem Diabetes Q4 Earnings Review: I Don't Share The Market's Skepticism
Tandem Diabetes Care, Inc. released its Q4 and full-year 2024 earnings after the bell yesterday, and the market has given the stock the thumbs down. Shares are down >30% in trading today, despite a beat on revenues of $940m, and on EPS, with a return to positive cash flow. Guidance for 2025 is for revenues of ~$1bn — the growth rate does not seem to have impressed Wall Street, and Q4 underperformance issues also played a part.
TNDM Stock Falls in Aftermarket Following Q4 Earnings and Revenue Miss
Tandem Diabetes' Q4 top and bottom lines lag their respective estimate. However, the company experiences strong sales growth both in and outside the United States.
Tandem Diabetes Care, Inc. (TNDM) Q4 2024 Earnings Call Transcript
Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Susan Morrison - Executive Vice President & Chief Administrative Officer John Sheridan - President & Chief Executive Officer Mark Novara - Executive Vice President & Chief Commercial Officer Leigh Vosseller - Executive Vice President & Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Steve Lichtman - Oppenheimer & Company Matt Miksic - Barclays Chris Pasquale - Nephron Research Larry Biegelsen - Wells Fargo Shagun Singh - RBC Mike Kratky - Leerink Partners Danielle Antalffy - UBS Jayson Bedford - Raymond James William Plovanic - Canaccord Genuity Mike Polark - Wolfe Research Matthew O'Brien - Piper Sandler Joshua Jennings - TD Cowen Jeff Johnson - Baird Travis Steed - Bank of America Operator Good day and welcome to the Tandem Diabetes Fourth Quarter and Year-End 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Here's What Key Metrics Tell Us About Tandem Diabetes Care (TNDM) Q4 Earnings
While the top- and bottom-line numbers for Tandem Diabetes Care (TNDM) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Tandem Diabetes Care, Inc. (TNDM) Reports Q4 Loss, Lags Revenue Estimates
Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.27 per share a year ago.
Tandem Diabetes Care (TNDM) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Evaluate the expected performance of Tandem Diabetes Care (TNDM) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Tandem Diabetes Gains 45.7% in a Year: What's Driving the Stock?
TNDM's shares rise as its expanding product portfolio gains market traction. However, the unfavorable macroeconomic scenario is concerning.
Reasons to Retain TNDM Stock in Your Portfolio for Now
A robust diabetes market and several strategic developments raise investors' optimism for Tandem Diabetes.
Tandem Diabetes Forges New R&D Agreement With UVA: Stock to Gain?
TNDM enters a multi-year research collaboration with the UVA Center for Diabetes Technology for the development of AID systems.
TNDM Stock to Gain From t:slim X2 With Dexcom G7 Launch in Canada
Tandem Diabetes' t:slim X2 insulin pump is now compatible with Dexcom G7 CGM in Canada.
Reasons to Retain TNDM Stock in Your Portfolio for Now
Innovations and a robust international market expansion raise investors' optimism for Tandem Diabetes.
TNDM Q3 Earnings Beat, '24 Sales View Up, Stock Falls in Aftermarket
Tandem Diabetes' top and bottom lines outpace estimates in the third quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.
